Precision BioLogic Announces Strategic Acquisition of George King Bio-Medical

Precision BioLogic Acquires George King Bio-Medical

HALIFAX, NS, October 16, 2025 – Precision BioLogic Inc., a leading developer of diagnostic products for blood coagulation disorders, is excited to announce the strategic acquisition of George King Bio-Medical, Inc. This move aligns both organizations in their commitment to patients with bleeding disorders, as George King Bio-Medical is renowned for its strong community ties and compassionate support for individuals affected by these conditions.

Paul Empey, President and CEO of Precision BioLogic, stated, "Since its inception more than 50 years ago, George King Bio-Medical has remained devoted to assisting individuals with blood coagulation disorders. Our two organizations share a similar mission, and together, we can continue to engage with our existing clients and partners while exploring new avenues to aid others in the bleeding disorders community."

Kathryn Blasco, CEO and President of George King Bio-Medical and daughter of the company’s founder, George King, echoed Empey's sentiments, emphasizing the potential for collaborative growth: "With Precision BioLogic, we can sustain our legacy of care and innovation. The future appears promising for both our organization and our customers."

Following this acquisition, both entities plan to focus on their customer bases and maintain regular operations, all while developing long-term strategic initiatives under the Precision BioLogic umbrella.

George King Bio-Medical, based in Overland Park, Kansas, was founded in 1973 out of a profound understanding of blood coagulation disorders and the financial burdens these conditions impose. The company specializes in providing high-quality fresh frozen human plasma for clinical laboratories, an area where it excels due to its commitment to product quality and customer service, alongside a growing plasma donor program. For more information about George King Bio-Medical, visit www.kingbiomed.com.

Precision BioLogic Inc. is well-known for its development, production, and distribution of the CRYOcheck™ product line, which is utilized globally by medical professionals for diagnosing coagulation disorders. The acquisition of Affinity Biologicals in November 2018 has enabled Precision BioLogic to expand its offerings for clinical and research applications, including a comprehensive range of coagulation-related antibodies and various products and services. Visit www.precisionbiologic.com for more details.

For additional inquiries, please contact Elaine Benoit, Marketing & Communications Manager, Precision BioLogic at [email protected] or 902.430.7795.